<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en" article-type="research-article">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Molecular Medicine Reports</journal-id>
<journal-title-group>
<journal-title>Molecular Medicine Reports</journal-title>
</journal-title-group>
<issn pub-type="ppub">1791-2997</issn>
<issn pub-type="epub">1791-3004</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3892/mmr.2025.13694</article-id>
<article-id pub-id-type="publisher-id">MMR-32-6-13694</article-id>
<article-categories>
<subj-group>
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Cholesterol metabolism in LUAD progression: GJB3 as a key target for cell-based therapeutic interventions</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author"><name><surname>Yan</surname><given-names>Qihang</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref>
<xref rid="af2-mmr-32-6-13694" ref-type="aff">2</xref>
<xref rid="fn1-mmr-32-6-13694" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Chang</surname><given-names>Wuguang</given-names></name>
<xref rid="af3-mmr-32-6-13694" ref-type="aff">3</xref>
<xref rid="fn1-mmr-32-6-13694" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Wong</surname><given-names>Wingshing</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref>
<xref rid="af2-mmr-32-6-13694" ref-type="aff">2</xref>
<xref rid="fn1-mmr-32-6-13694" ref-type="author-notes">&#x002A;</xref></contrib>
<contrib contrib-type="author"><name><surname>Gong</surname><given-names>Li</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Liang</surname><given-names>Dachuan</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Yang</surname><given-names>Jie</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref></contrib>
<contrib contrib-type="author"><name><surname>Wang</surname><given-names>Junye</given-names></name>
<xref rid="af1-mmr-32-6-13694" ref-type="aff">1</xref>
<xref rid="af2-mmr-32-6-13694" ref-type="aff">2</xref>
<xref rid="c1-mmr-32-6-13694" ref-type="corresp"/></contrib>
</contrib-group>
<aff id="af1-mmr-32-6-13694"><label>1</label>State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong 510060, P.R. China</aff>
<aff id="af2-mmr-32-6-13694"><label>2</label>Guangdong Esophageal Cancer Institute, Guangzhou, Guangdong 510060, P.R. China</aff>
<aff id="af3-mmr-32-6-13694"><label>3</label>Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong 519000, P.R. China</aff>
<author-notes>
<corresp id="c1-mmr-32-6-13694"><italic>Correspondence to</italic>: Dr Junye Wang, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, Guangdong 510060, P.R. China, E-mail: <email>wangjy@sysucc.org.cn</email></corresp>
<fn id="fn1-mmr-32-6-13694"><label>&#x002A;</label><p>Contributed equally</p></fn></author-notes>
<pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date>
<pub-date pub-type="epub"><day>26</day><month>09</month><year>2025</year></pub-date>
<volume>32</volume>
<issue>6</issue>
<elocation-id>329</elocation-id>
<history>
<date date-type="received"><day>18</day><month>02</month><year>2025</year></date>
<date date-type="accepted"><day>05</day><month>08</month><year>2025</year></date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; 2025 Yan et al.</copyright-statement>
<copyright-year>2025</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>Cholesterol metabolism reprogramming serves a pivotal role in tumor onset and progression. The present study investigated lung adenocarcinoma (LUAD), focusing on the regulatory impact of cholesterol metabolism-related genes (CMRGs). Consensus clustering identified distinct cholesterol metabolism-related clusters in LUAD, followed by survival analysis and immune infiltration profiling for each cluster. A predictive model, constructed using cluster-specific differentially expressed genes and the LASSO algorithm, was validated with an independent dataset. Furthermore, the model was utilized to predict potential responses to immunotherapy and chemotherapy for patients with LUAD. The functional role of the key gene GJB3 in LUAD progression was confirmed through <italic>in vitro</italic> experiments. Two distinct cholesterol metabolism-related clusters were identified, exhibiting significant differences in prognosis, biological function and immune cell infiltration. A survival model, based on four genes, demonstrated strong predictive performance across multiple datasets. The low-risk group showed improved responses to immunotherapy, while the high-risk group exhibited heightened sensitivity to chemotherapy. <italic>In vitro</italic> assays revealed that GJB3 knockdown suppressed LUAD cell proliferation and invasion, significantly reducing the expression of epithelial-mesenchymal transition-related genes. These findings highlight CMRGs as potential prognostic biomarkers and suggest a foundation for personalized treatment strategies in LUAD.</p>
</abstract>
<kwd-group>
<kwd>cholesterol metabolism</kwd>
<kwd>prognosis</kwd>
<kwd>lung adenocarcinoma</kwd>
<kwd>immunotherapy</kwd>
<kwd>GJB3</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Natural Science Foundation of Guangdong Province</funding-source>
<award-id>2019A1515011601</award-id>
</award-group>
<funding-statement>The present study was supported by the Natural Science Foundation of Guangdong Province (grant no. 2019A1515011601).</funding-statement>
</funding-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Lung cancer remains a leading cause of global mortality (<xref rid="b1-mmr-32-6-13694" ref-type="bibr">1</xref>), with tobacco use, occupational exposure and genetic factors being key contributors to its high incidence (<xref rid="b2-mmr-32-6-13694" ref-type="bibr">2</xref>). Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma are the two main subtypes of non-small-cell lung cancer (NSCLC) (<xref rid="b3-mmr-32-6-13694" ref-type="bibr">3</xref>). Notably, with the advent of precision medicine, treatment strategies for LUAD have undergone transformative changes, incorporating targeted therapy and immunotherapy (<xref rid="b4-mmr-32-6-13694" ref-type="bibr">4</xref>). However, genetic mutations, acquired resistance and epigenetic modifications inevitably lead to drug resistance in patients (<xref rid="b5-mmr-32-6-13694" ref-type="bibr">5</xref>). Therefore, identifying novel therapeutic markers to more accurately characterize LUAD is crucial for overcoming treatment resistance.</p>
<p>Cancer cells, which exhibit uncontrolled proliferation, require elevated cholesterol levels for membrane synthesis and other vital functions (<xref rid="b6-mmr-32-6-13694" ref-type="bibr">6</xref>), making cholesterol metabolism reprogramming a common feature in cancer. Dysregulation of proto-oncogenes and oncogenes results in notable increases in cholesterol uptake and the production of its derivatives within tumor cells (<xref rid="b7-mmr-32-6-13694" ref-type="bibr">7</xref>,<xref rid="b8-mmr-32-6-13694" ref-type="bibr">8</xref>). Additionally, the tumor microenvironment (TME), characterized by factors such as acidity and inflammation, further promotes cholesterol biosynthesis and uptake (<xref rid="b9-mmr-32-6-13694" ref-type="bibr">9</xref>,<xref rid="b10-mmr-32-6-13694" ref-type="bibr">10</xref>). 22-Hydroxycholesterol, a metabolite of cholesterol abundant in the TME (<xref rid="b11-mmr-32-6-13694" ref-type="bibr">11</xref>), recruits neutrophils by binding to CXCR2, thereby exerting immunosuppressive effects (<xref rid="b12-mmr-32-6-13694" ref-type="bibr">12</xref>). Tumor-associated macrophages also undergo functional and phenotypic alterations due to shifts in cholesterol metabolism, contributing to tumor progression (<xref rid="b13-mmr-32-6-13694" ref-type="bibr">13</xref>). In summary, cholesterol and its metabolites drive tumor progression by enhancing tumor malignancy and remodeling the TME. Therefore, statin-based inhibition of active cholesterol metabolism has emerged as a promising antitumor strategy (<xref rid="b14-mmr-32-6-13694" ref-type="bibr">14</xref>).</p>
<p>The aim of the present study was to identify potential biomarkers associated with cholesterol metabolism in the diagnosis of LUAD. The study aimed to screen differentially expressed genes related to cholesterol metabolism between LUAD and normal lung tissues, analyze their gene functions, and prognostic and clinical relevance, and perform cell experiments to validate the functions of the selected genes. The current study established a robust diagnostic and prognostic model for patients with LUAD.</p>
</sec>
<sec sec-type="materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Data collection and processing</title>
<p>RNA-sequencing data from patients with LUAD were obtained from The Cancer Genome Atlas (TCGA) database (<uri xlink:href="https://portal.gdc.cancer.gov/">https://portal.gdc.cancer.gov/</uri>), Subsequently, R project (v4.0.4; <uri xlink:href="https://www.r-project.org/">http://www.r-project.org/</uri>) was used for rigorous quality control and screening to remove duplicate samples, ensuring dataset uniqueness and reliability. Samples with a survival time of &#x003C;30 days were excluded to ensure complete and usable survival data. A training set consisting of 485 LUAD samples and 59 paracancerous tissues was selected from TCGA, and a validation set (GSE72094) (<xref rid="b15-mmr-32-6-13694" ref-type="bibr">15</xref>) was obtained from the Gene Expression Omnibus (<uri xlink:href="https://www.ncbi.nlm.nih.gov/gds">https://www.ncbi.nlm.nih.gov/gds</uri>), comprising 398 samples with complete clinical data. cholesterol metabolism-related genes (CMRGs) were downloaded from MSigDB (<uri xlink:href="https://www.gsea-msigdb.org/gsea/msigdb">https://www.gsea-msigdb.org/gsea/msigdb</uri>) (<xref rid="b16-mmr-32-6-13694" ref-type="bibr">16</xref>), totaling 158 genes.</p>
</sec>
<sec>
<title>Consensus cluster analysis</title>
<p>Univariate Cox regression analysis was performed to assess the relationship between CMRGs and prognosis. TCGA cohort was clustered using the consensus clustering algorithm implemented through the &#x2018;ConsensusClusterPlus&#x2019; R package (v3.0; <uri xlink:href="https://bioconductor.org/packages/3.0/bioc/html/ConsensusClusterPlus.html">http://bioconductor.org/packages/3.0/bioc/html/ConsensusClusterPlus.html</uri>) (<xref rid="b17-mmr-32-6-13694" ref-type="bibr">17</xref>). Clustering was conducted with the PAM algorithm based on 1-Pearson correlation distance, with 80&#x0025; of the samples repeated 1,000 times. The optimal number of clusters was determined through analysis of the empirical cumulative distribution function (CDF) plot. A Sankey diagram was generated using the &#x2018;ggplot2&#x2019; R package (v 3.3.0; <uri xlink:href="https://cran.r-project.org/web/packages/ggplot2/index.html">http://cran.r-project.org/web/packages/ggplot2/index.html</uri>).</p>
</sec>
<sec>
<title>Gene set enrichment analysis (GSEA)</title>
<p>GSEA was performed using &#x2018;c5.go.v7.5.1.symbols&#x2019; (Gene Ontology terms) and &#x2018;c2.cp.kegg.v7.5.1.symbols&#x2019; (Kyoto Encyclopedia of Genes and Genomes) from the molecular signature database (<uri xlink:href="https://www.gsea-msigdb.org/gsea/index.jsp">https://www.gsea-msigdb.org/gsea/index.jsp</uri>) to explore biological signatures and pathways across different clusters (<xref rid="b18-mmr-32-6-13694" ref-type="bibr">18</xref>).</p>
</sec>
<sec>
<title>TME analysis</title>
<p>Using the single sample GSEA algorithm, the activity levels of 28 immune cell types were evaluated for each sample (in the GSE72094 dataset) (<xref rid="b19-mmr-32-6-13694" ref-type="bibr">19</xref>). The ESTIMATE algorithm, applied to pre-screened immune-related gene expression data, was used to predict cell infiltration and tumor purity in LUAD tissues (TCGA) (<xref rid="b20-mmr-32-6-13694" ref-type="bibr">20</xref>).</p>
</sec>
<sec>
<title>Construction of cholesterol metabolism gene signature</title>
<p>Differentially expressed genes between clusters were identified using &#x2018;limma&#x2019; R package (v3.42.2; <uri xlink:href="https://bioconductor.org/packages/3.10/bioc/html/limma.html">http://bioconductor.org/packages/3.10/bioc/html/limma.html</uri>) analysis of variance (<xref rid="b21-mmr-32-6-13694" ref-type="bibr">21</xref>), and genes with a P-value of &#x003C;0.05 and fold change of &#x2265;2 were further analyzed using univariate or LASSO Cox regression. The risk index for each patient was calculated by multiplying the expression levels of target genes by their corresponding coefficients. Based on the median risk index, patients with LUAD were categorized into high-risk and low-risk groups for subsequent analyses. Kaplan-Meier curves and log-rank tests were used to assess survival differences, with the same analysis applied to validate the prognostic model in the GSE72094 dataset.</p>
</sec>
<sec>
<title>Nomogram development and validation</title>
<p>Univariate and multivariate Cox regression analyses were conducted using R project to assess the independence of the risk index from traditional clinical features. A nomogram was created to visually represent the significant risk index (P&#x003C;0.05) alongside other risk factors. Calibration curves and time-dependent receiver operating characteristic curves were generated to evaluate the prognostic predictive power of the nomogram at various time points.</p>
</sec>
<sec>
<title>Analysis of tumor mutation burden (TMB)</title>
<p>Somatic mutation data for LUAD cases were sourced from TCGA database, with TMB calculated by quantifying somatic non-synonymous mutations within defined genomic regions. The &#x2018;maftools_2.24.0&#x2019; R package (<uri xlink:href="https://bioconductor.org/packages/release/bioc/vignettes/maftools/inst/doc/maftools.html">https://bioconductor.org/packages/release/bioc/vignettes/maftools/inst/doc/maftools.html</uri>) was used to analyze the correlation between risk scores and TMB using the Pearson correlation coefficient.</p>
</sec>
<sec>
<title>Prediction of immunotherapy and chemotherapy response</title>
<p>The response of solid tumors to treatment with immune checkpoint inhibitors (ICIs) was predicted using the Tumor Immune Dysfunction and Exclusion (TIDE) (<uri xlink:href="https://tide.dfci.harvard.edu">http://tide.dfci.harvard.edu</uri>) algorithm, which evaluates immune cell infiltration and dysfunction levels (<xref rid="b22-mmr-32-6-13694" ref-type="bibr">22</xref>). The TIDE score for each patient with LUAD (from TCGA dataset) was calculated based on their expression profile, with higher TIDE scores indicating an increased potential for ICI resistance. Additionally, the &#x2018;pRRophetic_0.5&#x2019; R package (<uri xlink:href="https://github.com/paulgeeleher/pRRophetic2">https://github.com/paulgeeleher/pRRophetic2</uri>) was employed to estimate the half maximal inhibitory concentration values for various chemotherapy agents in patients with LUAD (from TCGA dataset).</p>
</sec>
<sec>
<title>Cell culture</title>
<p>Two human LUAD cell lines, A549 and NCI-H1975, were purchased from Wuhan Pricella Biotechnology Co., Ltd. A549 cells were cultured in F12K medium (Gibco; Thermo Fisher Scientific, Inc.), while NCI-H1975 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.). All of the media were supplemented with 10&#x0025; fetal bovine serum (NEWZERUM Ltd.) and 1&#x0025; penicillin/streptomycin in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C. Small interfering (si)RNAs were synthesized by Guangzhou RiboBio Co., Ltd. with the following sequences and targets (5&#x2032;-3&#x2032;): Non-targeting siRNA-negative control, antisense strand: ACGUGACACGUUCGGAGAA, sense strand: CUCCGAACGUGUCUCGUAA; GJB3-siRNA1, antisense strand: AGACCUUGUACCCACAGCGGG, sense strand: CGCUGUGGGUACAAGGUCUGC (target: CCCGCUGUGGGUACAAGGUCUGC); GJB3-siRNA2, antisense strand: AGGACUCGCCCACGCUAGUUU, sense strand: ACUAGCGUGGGCGAGUCCUGA, (target: AAACUAGCGUGGGCGAGUCCUGA); GJB3-siRNA3, antisense strand: UGGCGCGGGACCUUGACCGUG, sense strand: CGGUCAAGGUCCCGCGCCAAG (target: CACGGUCAAGGUCCCGCGCCAAG). Transfection was performed using Lipofectamine<sup>&#x00AE;</sup> RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.), and A549 and NCI-H1975 cells were used for transfection. Briefly, when the cell confluence was 30&#x2013;50&#x0025;, Opti-MEM (Gibco; Thermo Fisher Scientific, Inc.), 10 nm siRNA and Lipofectamine RNAiMAX reagent were successively added to a sterile microcentrifuge tube, gently mixed and incubated for 20 min at room temperature (25&#x00B0;C). After 20 min, the transfection complexes were successively added to the cell culture dishes, gently mixed and placed in the cell incubator for 6 h at 37&#x00B0;C. Subsequent experiments were performed 48 h after transfection.</p>
</sec>
<sec>
<title>Western blotting</title>
<p>After transfection, the cells were lysed with RIPA buffer (Merck KGaA) containing protease inhibitors (Merck KGaA). Protein concentrations were determined using the BCA kit (Nanjing KeyGen Biotech Co., Ltd.), and proteins (30 &#x00B5;g/lane) were separated by SDS-PAGE on 10&#x0025; gels. Following transfer to PVDF membranes (Merck KGaA), protein blocking was carried out with 5&#x0025; skim milk at room temperature for 1 h. The membranes were then incubated with primary antibodies overnight at 4&#x00B0;C, followed by secondary antibody incubation at room temperature for 1 h. Blots were detected using Ultra-sensitive ECL chemiluminescent substrate (cat. no. BL523B; Biosharp Life Sciences) and images were captured with a Tanon 5200 system (Tanon Science and Technology Co., Ltd.). The following antibodies were used for western blotting: GJB3 polyclonal antibody (cat. no. 12880-1-AP; Proteintech Group, Inc.), E-cadherin polyclonal antibody (cat. no. 20874-1-AP; Proteintech Group, Inc.), N-cadherin polyclonal antibody (cat. no. 22018-1-AP; Proteintech Group, Inc.), vimentin polyclonal antibody (cat. no. 10366-1-AP; Proteintech Group, Inc.), Snail1 polyclonal antibody (cat. no. 13099-1-AP; Proteintech Group, Inc.), &#x03B2;-actin recombinant antibody (cat. no. 81115-1-RR; Proteintech Group, Inc.) and Goat Anti-Rabbit IgG H&#x0026;L antibody (cat. no. BF03008; Biodragon).</p>
</sec>
<sec>
<title>Cell viability and proliferation assays</title>
<p>Cell viability was evaluated using the Cell Counting Kit (CCK)-8 (Dojindo Laboratories, Inc.). Cells were seeded in 96-well plates at 1,000 cells/well and cultured in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C. After 6 h, the cells adhered to the surface of the plates, and measurements at this time were considered 0-h data. Subsequently, CCK-8 values were measured every 24 h, and the data at 0, 24, 48, 72, 96 and 120 h time points were analyzed and plotted. Cells were seeded in 96-well plates and cultured in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C. Subsequently, 100 &#x00B5;l complete medium containing 10&#x0025; CCK-8 reagent was added to each well, and incubation was continued for 1 h. Absorbance at OD<sub>450</sub> was measured using the MD SpectraMax Plus 384 (Molecular Devices, Inc.).</p>
<p>On day 5 of culture, cell proliferation was assessed using the Click-iT EdU-488 Cell Proliferation Detection Kit (Wuhan Servicebio Technology Co., Ltd.), with 1 &#x00B5;g/ml Hoechst 33342 and 10 &#x00B5;M EdU used for detection. EdU staining experiments were performed according to the manufacturer&#x0027;s protocol. Images were captured using a Nikon ECLIPSE Ti-2 fluorescence microscope (Nikon Corporation), with excitation/emission wavelengths of 346/460 nm for Hoechst and 491/516 nm for EdU.</p>
</sec>
<sec>
<title>Colony formation assay</title>
<p>For colony formation assays, cells were seeded in 6-well plates at 1,000 cells/well and cultured in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C, with the medium changed every 3 days. After 2 weeks, the cells were fixed in 4&#x0025; paraformaldehyde at room temperature for 60 min and stained with 0.1&#x0025; crystal violet (Beyotime Institute of Biotechnology) at room temperature for 5 min. The colonies were rinsed with tap water, dried and images were captured using a digital camera. The data were statistically analyzed according to the area of crystal violet staining.</p>
</sec>
<sec>
<title>Migration and invasion assays</title>
<p>Cell migration and invasion were assessed using 24-well Transwell Tissue Culture Plate Inserts (pore size, 8.0 &#x00B5;m) (Guangzhou Jet Bio-Filtration Co., Ltd.). For the migration assay, 2,000 cells/well were seeded in the upper chamber of an uncoated Transwell insert, whereas for the invasion assay, the upper chamber was coated with VitroGel<sup>&#x2122;</sup> 3D hydrogel (cat. no. VHM01; Shanghai XP Biomed Ltd.) at room temperature for 10&#x2013;15 min. The cells were seeded in the upper chamber in serum-free medium, whereas the lower chamber contained complete medium; the cells were cultured in a 5&#x0025; CO<sub>2</sub> incubator at 37&#x00B0;C. After 24 h of incubation, the cells were fixed with 4&#x0025; paraformaldehyde at room temperature for 60 min and stained with 0.1&#x0025; crystal violet at room temperature for 5 min. After rinsing with tap water and drying, images were captured using Nikon ECLIPSE Ti-2 light microscope channel (Nikon Corporation).</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>Data analysis and image processing were performed using R software (version 4.1.3) (<uri xlink:href="https://www.r-project.org/">https://www.r-project.org/</uri>) and GraphPad Prism 9 (Dotmatics). Differences between continuous variables were analyzed using the Wilcoxon rank-sum test, while categorical variables were assessed using the &#x03C7;<sup>2</sup> test. Survival analysis was conducted using the log-rank test. Spearman&#x0027;s rank correlation was applied for correlation analysis. P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Features of cholesterol metabolism in LUAD identified by consensus clustering</title>
<p>Univariate Cox regression analysis was performed on 158 CMRGs, revealing that 44 of these genes were significantly associated with prognosis in LUAD (<xref rid="SD2-mmr-32-6-13694" ref-type="supplementary-material">Table SI</xref>). Most of these 44 genes exhibited marked differential expression between LUAD and normal tissues (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1A</xref>). These 44 genes were further used to classify LUAD into two distinct cholesterol metabolism clusters based on their expression patterns (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1B</xref>). This clustering was validated by observing relative changes in the CDF curves (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1C</xref>) and the area under the curve (AUC) of CDF curves (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1D</xref>), with the optimal division (k=2) indicating the ideal number of clusters. When k=2, the delta area of CDF began to markedly decrease, thus choosing k=2 gave the best clustering effect (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1C and D</xref>). Survival analysis showed a significant difference in prognosis between the two clusters (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1E</xref>), with the Sankey diagram highlighting that cluster 1 contained more patients with lower Tumor-Node-Metastasis stages (<xref rid="b23-mmr-32-6-13694" ref-type="bibr">23</xref>) and a better prognosis (<xref rid="f1-mmr-32-6-13694" ref-type="fig">Fig. 1F</xref>).</p>
</sec>
<sec>
<title>Potential functional pathways analysis</title>
<p>GSEA of Gene Ontology terms revealed that cluster 1 was primarily involved in &#x2018;POSITIVE REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION&#x2019;, &#x2018;REGULATION OF CHOLESTEROL EFFLUX&#x2019; and &#x2018;NEGATIVE REGULATION OF LIPID CATABOLIC PROCESS&#x2019; (<xref rid="f2-mmr-32-6-13694" ref-type="fig">Fig. 2A</xref>). Given that enhanced cholesterol metabolism in tumors is associated with poor prognosis (<xref rid="b24-mmr-32-6-13694" ref-type="bibr">24</xref>), these processes in cluster 1, which inhibit cholesterol metabolism and reduce the enrichment of cholesterol metabolites, were linked to a more favorable prognosis. Conversely, cluster 2 exhibited significant enrichment in processes such as &#x2018;CELL CYCLE CHECKPOINT SIGNALING&#x2019;, &#x2018;MEIOTIC CELL CYCLE PROCESS&#x2019;, &#x2018;MITOTIC CELL CYCLE CHECKPOINT SIGNALING&#x2019;, &#x2018;DNA DEPENDENT DNA REPLICATION&#x2019; and &#x2018;DNA RECOMBINATION&#x2019;, contributing to accelerated tumor progression (<xref rid="f2-mmr-32-6-13694" ref-type="fig">Fig. 2B</xref>). These findings were corroborated by Kyoto Encyclopedia of Genes and Genomes pathway analysis (<xref rid="f2-mmr-32-6-13694" ref-type="fig">Fig. 2C and D</xref>).</p>
</sec>
<sec>
<title>Immune infiltration analysis</title>
<p>Cholesterol metabolism reprogramming has been shown to be significantly associated with the formation of an immunosuppressive microenvironment (<xref rid="b6-mmr-32-6-13694" ref-type="bibr">6</xref>). To investigate this further, the infiltration of 28 immune cell types was assessed across the clusters. Cluster 1, with a better prognosis, exhibited more abundant immune cell infiltration (<xref rid="f3-mmr-32-6-13694" ref-type="fig">Fig. 3A</xref>), with the majority of these cells having antitumor effects, such as B cells, macrophages, mast cells, natural killer cells, T follicular helper cells and type 17 T helper cells (<xref rid="b25-mmr-32-6-13694" ref-type="bibr">25</xref>). Additionally, the ESTIMATE algorithm analysis confirmed the higher levels of immune cell infiltration in cluster 1 (<xref rid="f3-mmr-32-6-13694" ref-type="fig">Fig. 3B-D</xref>). Furthermore, the expression of immunosuppressive checkpoints is known to be associated with immunotherapy responses (<xref rid="b26-mmr-32-6-13694" ref-type="bibr">26</xref>), and most immunosuppressive checkpoints commonly targeted in clinical practice were more closely associated with cluster 2, such as CD274, CD276, LAG3, PDCD1 and PDCD1LG2 (<xref rid="f3-mmr-32-6-13694" ref-type="fig">Fig. 3E</xref>).</p>
</sec>
<sec>
<title>Construction and validation of CMRG signature</title>
<p>Limma differential analysis identified 124 differentially expressed genes between cluster 1 and cluster 2. Univariate Cox regression identified 85 genes associated with prognosis (<xref rid="SD2-mmr-32-6-13694" ref-type="supplementary-material">Table SII</xref>). Using the optimal &#x03BB; value (<xref rid="f4-mmr-32-6-13694" ref-type="fig">Fig. 4A and B</xref>), four key genes: CYP4B1, GJB3, IGF2BP1 and KRT6A, were identified as significantly influencing the prognosis of the two clusters. The risk score for each patient was calculated using the following formula: Risk score=CYP4B1 &#x00D7; &#x2212;0.01406345 &#x002B; GJB3 &#x00D7; 0.03109533 &#x002B; IGF2BP1 &#x00D7; 0.06671392 &#x002B; KRT6A &#x00D7; 0.02723521. This model effectively distinguished patient prognoses in TCGA-LUAD cohort (<xref rid="f4-mmr-32-6-13694" ref-type="fig">Fig. 4C</xref>). The risk factor distribution graph demonstrated a higher mortality rate in the high-risk group (<xref rid="f4-mmr-32-6-13694" ref-type="fig">Fig. 4D</xref>), and the heatmap illustrated the distribution of the four key genes across different patients (<xref rid="f4-mmr-32-6-13694" ref-type="fig">Fig. 4E</xref>). Applying the same risk score formula to the GSE72094 dataset yielded similar results (<xref rid="f4-mmr-32-6-13694" ref-type="fig">Fig. 4F-H</xref>), further validating the effectiveness of the prognostic model.</p>
</sec>
<sec>
<title>Construction and validation of the nomogram</title>
<p>Univariate and multivariate Cox regression analyses of the key features affecting prognosis found that CMRG risk signature was an independent prognostic risk factor (<xref rid="f5-mmr-32-6-13694" ref-type="fig">Fig. 5A and B</xref>). Based on the CMRG risk signature and clinical characteristics, a nomogram prediction model was constructed (<xref rid="f5-mmr-32-6-13694" ref-type="fig">Fig. 5C</xref>). The AUC values for 1-, 3- and 5-year predictions were 0.742, 0.735 and 0.733, respectively (<xref rid="f5-mmr-32-6-13694" ref-type="fig">Fig. 5D</xref>). In addition, the prediction results of the nomogram closely aligned with the actual outcomes (<xref rid="f5-mmr-32-6-13694" ref-type="fig">Fig. 5E</xref>).</p>
</sec>
<sec>
<title>Analysis of TMB</title>
<p>Gene mutations are critical factors influencing tumor prognosis (<xref rid="b27-mmr-32-6-13694" ref-type="bibr">27</xref>). TMB analysis of patients in different risk groups showed that most of the top 10 mutated genes overlapped between the two groups (<xref rid="f6-mmr-32-6-13694" ref-type="fig">Fig. 6A and B</xref>), but mutation incidence was higher in the high-risk group (<xref rid="f6-mmr-32-6-13694" ref-type="fig">Fig. 6C</xref>). In addition, a low positive association was confirmed between risk score and TMB (<xref rid="f6-mmr-32-6-13694" ref-type="fig">Fig. 6D</xref>).</p>
</sec>
<sec>
<title>Prediction of immunotherapy and chemotherapy response</title>
<p>Using the TIDE algorithm, the potential effects of immunotherapy for patients with LUAD were successfully modeled and predicted. Notably, high-risk patients exhibited higher exclusion scores and TIDE values, while there was no significant difference in dysfunction scores (<xref rid="f7-mmr-32-6-13694" ref-type="fig">Fig. 7A</xref>), indicating a greater likelihood of drug resistance during immunotherapy compared with low-risk patients. Further analysis revealed that the percentage of low-risk patients responding positively to immunotherapy was significantly higher than that of high-risk patients (<xref rid="f7-mmr-32-6-13694" ref-type="fig">Fig. 7B</xref>), providing valuable insights for clinical decision-making. Additionally, the sensitivity of various chemotherapeutic agents within the patient cohort was assessed. Multiple chemotherapy drugs, such as cisplatin, docetaxel and doxorubicin, showed lower half-maximal inhibitory concentration values in the high-risk group, indicating that high-risk patients were more likely to benefit from these chemotherapy drugs (<xref rid="f7-mmr-32-6-13694" ref-type="fig">Fig. 7C</xref>), offering an expanded understanding of treatment options and providing a scientific foundation for personalized treatment strategies.</p>
</sec>
<sec>
<title>GJB3 promotes the proliferation, invasion and epithelial-mesenchymal transition (EMT) of LUAD</title>
<p>Bioinformatics analysis revealed that GJB3 was highly expressed in tumor tissues and functioned as an oncogene (<xref rid="SD2-mmr-32-6-13694" ref-type="supplementary-material">Table SII</xref>). This was confirmed through <italic>in vitro</italic> validation. siRNA-mediated knockdown of GJB3 expression in A549 and NCI-H1975 cells (<xref rid="f8-mmr-32-6-13694" ref-type="fig">Fig. 8A and H</xref>) resulted in significantly reduced cell viability (<xref rid="f8-mmr-32-6-13694" ref-type="fig">Fig. 8B</xref>). In addition, EdU staining and colony formation assays showed that GJB3 knockdown decreased the proliferative capacity of both A549 and NCI-H1975 cells (<xref rid="f8-mmr-32-6-13694" ref-type="fig">Fig. 8C and D</xref>, and <xref rid="SD1-mmr-32-6-13694" ref-type="supplementary-material">S1</xref>). Transwell assays further demonstrated that GJB3 knockdown inhibited the migration and invasion of these cells (<xref rid="f8-mmr-32-6-13694" ref-type="fig">Fig. 8E and F</xref>). Given that GJB3 encodes a key member of the connexin gene family (<xref rid="b28-mmr-32-6-13694" ref-type="bibr">28</xref>), its alteration might impact EMT. Further examination revealed that GJB3 knockdown downregulated the expression levels of vimentin, Snail1 and N-cadherin, while upregulating E-cadherin levels in A549 and NCI-H1975 cells (<xref rid="f8-mmr-32-6-13694" ref-type="fig">Fig. 8G</xref>), thus indicating that GJB3 knockdown inhibited the EMT process in these cell lines.</p>
</sec>
</sec>
</sec>
<sec sec-type="discussion">
<title>Discussion</title>
<p>The treatment of NSCLC faces notable challenges, including treatment resistance and the need for personalized therapies. Although traditional chemotherapy and radiotherapy remain essential components of NSCLC management, innovative treatment strategies have emerged in recent years (<xref rid="b29-mmr-32-6-13694" ref-type="bibr">29</xref>). Immunotherapy, such as anti-PD-1/PD-L1 therapy, one of the most promising advancements, has demonstrated marked therapeutic effects and survival benefits by stimulating the immune system of patients to target and eliminate cancer cells (<xref rid="b30-mmr-32-6-13694" ref-type="bibr">30</xref>). By contrast, targeted therapies, such as EGFR-tyrosine kinase inhibitors (TKIs), ALK-TKIs and entrectinib, offer more tailored treatment options by focusing on specific molecular markers on tumor cells, enabling precise intervention. By identifying and targeting these markers with specific drugs, targeted therapies enhance treatment efficacy, improve patient quality of life and minimize side effects (<xref rid="b31-mmr-32-6-13694" ref-type="bibr">31</xref>&#x2013;<xref rid="b33-mmr-32-6-13694" ref-type="bibr">33</xref>). Furthermore, genomics-guided therapy represents a new frontier in personalized treatment for NSCLC. By analyzing the genetic profile of tumors, this approach provides deeper insights into the genetic characteristics, mutations and potential resistance mechanisms of the tumor, enabling the development of more precise and effective treatment strategies (<xref rid="b34-mmr-32-6-13694" ref-type="bibr">34</xref>). The combination of immunotherapy and targeted therapies has further advanced NSCLC treatment, leveraging the synergistic effects of both approaches to improve therapeutic outcomes while minimizing adverse effects, thus offering patients greater survival benefits and a better overall treatment experience (<xref rid="b35-mmr-32-6-13694" ref-type="bibr">35</xref>).</p>
<p>Cholesterol serves a pivotal role in maintaining cellular homeostasis (<xref rid="b36-mmr-32-6-13694" ref-type="bibr">36</xref>). Due to the limited availability of nutrients in local tissues, tumors often experience relative nutrient deficiencies alongside the accumulation of metabolic waste products (<xref rid="b37-mmr-32-6-13694" ref-type="bibr">37</xref>). In response to these adverse conditions, tumors undergo metabolic reprogramming to adapt (<xref rid="b38-mmr-32-6-13694" ref-type="bibr">38</xref>). Preclinical studies have shown that inhibiting cholesterol synthesis can restrict tumor progression (<xref rid="b39-mmr-32-6-13694" ref-type="bibr">39</xref>,<xref rid="b40-mmr-32-6-13694" ref-type="bibr">40</xref>), and promising results have been reported from combining statins with other treatment modalities (<xref rid="b41-mmr-32-6-13694" ref-type="bibr">41</xref>,<xref rid="b42-mmr-32-6-13694" ref-type="bibr">42</xref>). Identifying key molecules involved in cholesterol metabolism and developing targeted drugs against them are critical steps in advancing treatment for LUAD.</p>
<p>Cholesterol metabolism influences both tumor growth and the immune microenvironment (<xref rid="b43-mmr-32-6-13694" ref-type="bibr">43</xref>), indicating a complex crosstalk between cholesterol metabolic status and the TME. Two distinct clusters with different cholesterol metabolism profiles were identified in the present study, with cluster 1 exhibiting richer immune cell infiltration, which helps explain the prognostic differences in patients with LUAD. Given the strong association between cholesterol metabolism and prognosis in LUAD, a prognostic model based on cholesterol metabolism was developed, involving CYP4B1, GJB3, IGF2BP1 and KRT6A. CYP4B1, a member of the cytochrome P450 enzyme superfamily, serves a key role in cholesterol and derivative synthesis. Its elevated expression in bladder cancer has been linked to an increased risk of the disease (<xref rid="b44-mmr-32-6-13694" ref-type="bibr">44</xref>). IGF2BP1 influences tumor development and therapeutic responses primarily by binding to mRNAs, regulating their stability and translation (<xref rid="b45-mmr-32-6-13694" ref-type="bibr">45</xref>). M&#x00FC;ller <italic>et al</italic> (<xref rid="b46-mmr-32-6-13694" ref-type="bibr">46</xref>) demonstrated that IGF2BP1 promotes SRF expression in an m6A-dependent manner, driving tumor growth and invasion. Additionally, Zhang <italic>et al</italic> (<xref rid="b47-mmr-32-6-13694" ref-type="bibr">47</xref>) showed that IGF2BP1 overexpression accelerates the malignant progression of endometrial cancer through m6A methylation. Together, these studies highlight the importance of IGF2BP1 in understanding cancer progression. KRT6A is positively associated with both T-stage and N-stage in LUAD, and its knockdown inhibits cell proliferation, invasion and the EMT process in LUAD (<xref rid="b48-mmr-32-6-13694" ref-type="bibr">48</xref>). Furthermore, GJB3 has been shown to be markedly upregulated in the liver metastases of pancreatic cancer, with overexpression enhancing the accumulation of tumor-associated neutrophils and promoting liver metastasis (<xref rid="b49-mmr-32-6-13694" ref-type="bibr">49</xref>). The current study focused on GJB3, which is a member of the cell junction protein family. According to a previous report, high cholesterol metabolism can affect cell adhesion and promote tumor metastasis (<xref rid="b50-mmr-32-6-13694" ref-type="bibr">50</xref>), and GJB3 may have an important role in this process. To further investigate its function, <italic>in vitro</italic> experiments were conducted, revealing that GJB3 knockdown inhibited the proliferative ability of LUAD cells, consistent with the results from GSEA. Additionally, GJB3 knockdown suppressed the migration and invasion of LUAD cells and reduced the expression of EMT-related proteins. These findings suggested that GJB3 may serve a critical role in LUAD progression and could serve as a potential therapeutic target.</p>
<p>Cholesterol metabolism influences the TME and may significantly affect the efficacy of immunotherapy (<xref rid="b51-mmr-32-6-13694" ref-type="bibr">51</xref>). The CMRG score constructed in the current study suggested that low-risk patients exhibited higher response rates to immune checkpoint therapy, whereas high-risk patients were predicted to show a better chemotherapy response. This highlights new perspectives for the precision treatment of patients with LUAD.</p>
<p>There are some limitations in the present study: The sequencing data comes from previous patients, and the characteristics of cholesterol metabolism were only studied in TCGA and GSE72094 datasets. It is necessary to conduct larger prospective studies to further confirm the effectiveness of the prognostic model. Second, the cancer-promoting ability of GJB3 in LUAD needs further validation in animals. Notably, the mechanism by which GJB3 promotes the progression of LUAD by affecting cholesterol metabolism needs to be further studied through multi-omics, and <italic>in vitro</italic> and <italic>in vivo</italic> experiments.</p>
<p>In conclusion, cholesterol metabolic status is closely associated with the prognosis, TME and treatment response in patients with LUAD. The cholesterol metabolism-related prognostic model developed in the current study may not only predict patient outcomes but could also provide valuable insights into personalized treatment strategies.</p>
</sec>
<sec sec-type="supplementary-material">
<title>Supplementary Material</title>
<supplementary-material id="SD1-mmr-32-6-13694" content-type="local-data">
<caption>
<title>Supporting Data</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data1.pdf"/>
</supplementary-material>
<supplementary-material id="SD2-mmr-32-6-13694" content-type="local-data">
<caption>
<title>Supporting Data</title>
</caption>
<media mimetype="application" mime-subtype="pdf" xlink:href="Supplementary_Data2.pdf"/>
</supplementary-material>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec sec-type="data-availability">
<title>Availability of data and materials</title>
<p>The data generated in the present study may be requested from the corresponding author.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>QY, WC and JW designed and supervised the experiments. WC and WW performed the bioinformatics analysis. LG and DL performed the experiments. QY and JY analyzed and interpreted the data, and wrote the first draft of the manuscript. QY, JW and WC reviewed the manuscript. LG and WC confirm the authenticity of all the raw data. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec sec-type="COI-statement">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-mmr-32-6-13694"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2020</article-title><source>CA Cancer J Clin</source><volume>70</volume><fpage>7</fpage><lpage>30</lpage><year>2020</year></element-citation></ref>
<ref id="b2-mmr-32-6-13694"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berg</surname><given-names>CD</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Boffetta</surname><given-names>P</given-names></name><name><surname>Cai</surname><given-names>J</given-names></name><name><surname>Connolly</surname><given-names>C</given-names></name><name><surname>Kerpel-Fronius</surname><given-names>A</given-names></name><name><surname>Kitts</surname><given-names>AB</given-names></name><name><surname>Lam</surname><given-names>DCL</given-names></name><name><surname>Mohan</surname><given-names>A</given-names></name><name><surname>Myers</surname><given-names>R</given-names></name><etal/></person-group><article-title>Air pollution and lung cancer: A review by international association for the study of lung cancer early detection and screening committee</article-title><source>J Thorac Oncol</source><volume>18</volume><fpage>1277</fpage><lpage>1289</lpage><year>2023</year><pub-id pub-id-type="doi">10.1016/j.jtho.2023.05.024</pub-id></element-citation></ref>
<ref id="b3-mmr-32-6-13694"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ak&#x00E7;ay</surname><given-names>S</given-names></name></person-group><article-title>Deciphering molecular overlaps between COPD and NSCLC subtypes (LUAD and LUSC): An integrative bioinformatics study</article-title><source>Medicine (Baltimore)</source><volume>104</volume><fpage>e43906</fpage><year>2025</year><pub-id pub-id-type="doi">10.1097/MD.0000000000043906</pub-id></element-citation></ref>
<ref id="b4-mmr-32-6-13694"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thai</surname><given-names>AA</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Sequist</surname><given-names>LV</given-names></name><name><surname>Gainor</surname><given-names>JF</given-names></name><name><surname>Heist</surname><given-names>RS</given-names></name></person-group><article-title>Lung cancer</article-title><source>Lancet</source><volume>398</volume><fpage>535</fpage><lpage>554</lpage><year>2021</year><pub-id pub-id-type="doi">10.1016/S0140-6736(21)00312-3</pub-id></element-citation></ref>
<ref id="b5-mmr-32-6-13694"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mamdani</surname><given-names>H</given-names></name><name><surname>Matosevic</surname><given-names>S</given-names></name><name><surname>Khalid</surname><given-names>AB</given-names></name><name><surname>Durm</surname><given-names>G</given-names></name><name><surname>Jalal</surname><given-names>SI</given-names></name></person-group><article-title>Immunotherapy in lung cancer: Current landscape and future directions</article-title><source>Front Immunol</source><volume>13</volume><fpage>823618</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fimmu.2022.823618</pub-id></element-citation></ref>
<ref id="b6-mmr-32-6-13694"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Song</surname><given-names>BL</given-names></name><name><surname>Xu</surname><given-names>C</given-names></name></person-group><article-title>Cholesterol metabolism in cancer: Mechanisms and therapeutic opportunities</article-title><source>Nat Metab</source><volume>2</volume><fpage>132</fpage><lpage>141</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s42255-020-0174-0</pub-id></element-citation></ref>
<ref id="b7-mmr-32-6-13694"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakiri</surname><given-names>L</given-names></name><name><surname>Hamacher</surname><given-names>R</given-names></name><name><surname>Gra&#x00F1;a</surname><given-names>O</given-names></name><name><surname>Gu&#x00ED;o-Carri&#x00F3;n</surname><given-names>A</given-names></name><name><surname>Campos-Olivas</surname><given-names>R</given-names></name><name><surname>Martinez</surname><given-names>L</given-names></name><name><surname>Dienes</surname><given-names>HP</given-names></name><name><surname>Thomsen</surname><given-names>MK</given-names></name><name><surname>Hasenfuss</surname><given-names>SC</given-names></name><name><surname>Wagner</surname><given-names>EF</given-names></name></person-group><article-title>Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation</article-title><source>J Exp Med</source><volume>214</volume><fpage>1387</fpage><lpage>1409</lpage><year>2017</year><pub-id pub-id-type="doi">10.1084/jem.20160935</pub-id></element-citation></ref>
<ref id="b8-mmr-32-6-13694"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>Q</given-names></name><name><surname>Prager</surname><given-names>BC</given-names></name><name><surname>Mack</surname><given-names>SC</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>LJY</given-names></name><name><surname>Gimple</surname><given-names>RC</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>S</given-names></name><etal/></person-group><article-title>MYC-regulated mevalonate metabolism maintains brain tumor-initiating cells</article-title><source>Cancer Res</source><volume>77</volume><fpage>4947</fpage><lpage>4960</lpage><year>2017</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-17-0114</pub-id></element-citation></ref>
<ref id="b9-mmr-32-6-13694"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>A</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Nakaki</surname><given-names>R</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Hamakubo</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>J</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Yoshida</surname><given-names>T</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Osawa</surname><given-names>T</given-names></name></person-group><article-title>Extracellular acidic pH activates the sterol regulatory element-binding protein 2 to promote tumor progression</article-title><source>Cell Rep</source><volume>18</volume><fpage>2228</fpage><lpage>2242</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.celrep.2017.02.006</pub-id></element-citation></ref>
<ref id="b10-mmr-32-6-13694"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name><name><surname>Lv</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Huang</surname><given-names>P</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name></person-group><article-title>Pro-inflammation NF-&#x03BA;B signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells</article-title><source>J Exp Clin Cancer Res</source><volume>36</volume><fpage>15</fpage><year>2017</year><pub-id pub-id-type="doi">10.1186/s13046-017-0490-8</pub-id></element-citation></ref>
<ref id="b11-mmr-32-6-13694"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kloudova</surname><given-names>A</given-names></name><name><surname>Guengerich</surname><given-names>FP</given-names></name><name><surname>Soucek</surname><given-names>P</given-names></name></person-group><article-title>The role of oxysterols in human cancer</article-title><source>Trends Endocrinol Metab</source><volume>28</volume><fpage>485</fpage><lpage>496</lpage><year>2017</year><pub-id pub-id-type="doi">10.1016/j.tem.2017.03.002</pub-id></element-citation></ref>
<ref id="b12-mmr-32-6-13694"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raccosta</surname><given-names>L</given-names></name><name><surname>Fontana</surname><given-names>R</given-names></name><name><surname>Maggioni</surname><given-names>D</given-names></name><name><surname>Lanterna</surname><given-names>C</given-names></name><name><surname>Villablanca</surname><given-names>EJ</given-names></name><name><surname>Paniccia</surname><given-names>A</given-names></name><name><surname>Musumeci</surname><given-names>A</given-names></name><name><surname>Chiricozzi</surname><given-names>E</given-names></name><name><surname>Trincavelli</surname><given-names>ML</given-names></name><name><surname>Daniele</surname><given-names>S</given-names></name><etal/></person-group><article-title>The oxysterol-CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils</article-title><source>J Exp Med</source><volume>210</volume><fpage>1711</fpage><lpage>1728</lpage><year>2013</year><pub-id pub-id-type="doi">10.1084/jem.20130440</pub-id></element-citation></ref>
<ref id="b13-mmr-32-6-13694"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goossens</surname><given-names>P</given-names></name><name><surname>Rodriguez-Vita</surname><given-names>J</given-names></name><name><surname>Etzerodt</surname><given-names>A</given-names></name><name><surname>Masse</surname><given-names>M</given-names></name><name><surname>Rastoin</surname><given-names>O</given-names></name><name><surname>Gouirand</surname><given-names>V</given-names></name><name><surname>Ulas</surname><given-names>T</given-names></name><name><surname>Papantonopoulou</surname><given-names>O</given-names></name><name><surname>Van Eck</surname><given-names>M</given-names></name><name><surname>Auphan-Anezin</surname><given-names>N</given-names></name><etal/></person-group><article-title>Membrane cholesterol efflux drives tumor-associated macrophage reprogramming and tumor progression</article-title><source>Cell Metab</source><volume>29</volume><fpage>1376</fpage><lpage>1389.e4</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.cmet.2019.02.016</pub-id></element-citation></ref>
<ref id="b14-mmr-32-6-13694"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kopecka</surname><given-names>J</given-names></name><name><surname>Trouillas</surname><given-names>P</given-names></name><name><surname>Ga&#x0161;parovi&#x0107;</surname><given-names>A&#x010C;</given-names></name><name><surname>Gazzano</surname><given-names>E</given-names></name><name><surname>Assaraf</surname><given-names>YG</given-names></name><name><surname>Riganti</surname><given-names>C</given-names></name></person-group><article-title>Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets</article-title><source>Drug Resist Updat</source><volume>49</volume><fpage>100670</fpage><year>2020</year><pub-id pub-id-type="doi">10.1016/j.drup.2019.100670</pub-id></element-citation></ref>
<ref id="b15-mmr-32-6-13694"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schabath</surname><given-names>MB</given-names></name><name><surname>Welsh</surname><given-names>EA</given-names></name><name><surname>Fulp</surname><given-names>WJ</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Teer</surname><given-names>JK</given-names></name><name><surname>Thompson</surname><given-names>ZJ</given-names></name><name><surname>Engel</surname><given-names>BE</given-names></name><name><surname>Xie</surname><given-names>M</given-names></name><name><surname>Berglund</surname><given-names>AE</given-names></name><name><surname>Creelan</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma</article-title><source>Oncogene</source><volume>35</volume><fpage>3209</fpage><lpage>3216</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/onc.2015.375</pub-id></element-citation></ref>
<ref id="b16-mmr-32-6-13694"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Castanza</surname><given-names>AS</given-names></name><name><surname>Recla</surname><given-names>JM</given-names></name><name><surname>Eby</surname><given-names>D</given-names></name><name><surname>Thorvaldsdottir</surname><given-names>H</given-names></name><name><surname>Bult</surname><given-names>CJ</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Extending support for mouse data in the molecular signatures database (MSigDB)</article-title><source>Nat Methods</source><volume>20</volume><fpage>1619</fpage><lpage>1620</lpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41592-023-02014-7</pub-id></element-citation></ref>
<ref id="b17-mmr-32-6-13694"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkerson</surname><given-names>MD</given-names></name><name><surname>Hayes</surname><given-names>DN</given-names></name></person-group><article-title>ConsensusClusterPlus: A class discovery tool with confidence assessments and item tracking</article-title><source>Bioinformatics</source><volume>26</volume><fpage>1572</fpage><lpage>1573</lpage><year>2010</year><pub-id pub-id-type="doi">10.1093/bioinformatics/btq170</pub-id></element-citation></ref>
<ref id="b18-mmr-32-6-13694"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Mootha</surname><given-names>VK</given-names></name><name><surname>Mukherjee</surname><given-names>S</given-names></name><name><surname>Ebert</surname><given-names>BL</given-names></name><name><surname>Gillette</surname><given-names>MA</given-names></name><name><surname>Paulovich</surname><given-names>A</given-names></name><name><surname>Pomeroy</surname><given-names>SL</given-names></name><name><surname>Golub</surname><given-names>TR</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><article-title>Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles</article-title><source>Proc Natl Acad Sci USA</source><volume>102</volume><fpage>15545</fpage><lpage>15550</lpage><year>2005</year><pub-id pub-id-type="doi">10.1073/pnas.0506580102</pub-id></element-citation></ref>
<ref id="b19-mmr-32-6-13694"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Barbie</surname><given-names>DA</given-names></name><name><surname>Tamayo</surname><given-names>P</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Moody</surname><given-names>SE</given-names></name><name><surname>Dunn</surname><given-names>IF</given-names></name><name><surname>Schinzel</surname><given-names>AC</given-names></name><name><surname>Sandy</surname><given-names>P</given-names></name><name><surname>Meylan</surname><given-names>E</given-names></name><name><surname>Scholl</surname><given-names>C</given-names></name><etal/></person-group><article-title>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</article-title><source>Nature</source><volume>462</volume><fpage>108</fpage><lpage>112</lpage><year>2009</year><pub-id pub-id-type="doi">10.1038/nature08460</pub-id></element-citation></ref>
<ref id="b20-mmr-32-6-13694"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshihara</surname><given-names>K</given-names></name><name><surname>Shahmoradgoli</surname><given-names>M</given-names></name><name><surname>Martinez</surname><given-names>E</given-names></name><name><surname>Vegesna</surname><given-names>R</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Torres-Garcia</surname><given-names>W</given-names></name><name><surname>Trevi&#x00F1;o</surname><given-names>V</given-names></name><name><surname>Shen</surname><given-names>H</given-names></name><name><surname>Laird</surname><given-names>PW</given-names></name><name><surname>Levine</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Inferring tumour purity and stromal and immune cell admixture from expression data</article-title><source>Nat Commun</source><volume>4</volume><fpage>2612</fpage><year>2013</year><pub-id pub-id-type="doi">10.1038/ncomms3612</pub-id></element-citation></ref>
<ref id="b21-mmr-32-6-13694"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ritchie</surname><given-names>ME</given-names></name><name><surname>Phipson</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Law</surname><given-names>CW</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Smyth</surname><given-names>GK</given-names></name></person-group><article-title>limma powers differential expression analyses for RNA-sequencing and microarray studies</article-title><source>Nucleic Acids Res</source><volume>43</volume><fpage>e47</fpage><year>2015</year><pub-id pub-id-type="doi">10.1093/nar/gkv007</pub-id></element-citation></ref>
<ref id="b22-mmr-32-6-13694"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Sahu</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Traugh</surname><given-names>N</given-names></name><name><surname>Bu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response</article-title><source>Nat Med</source><volume>24</volume><fpage>1550</fpage><lpage>1558</lpage><year>2018</year><pub-id pub-id-type="doi">10.1038/s41591-018-0136-1</pub-id></element-citation></ref>
<ref id="b23-mmr-32-6-13694"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rami-Porta</surname><given-names>R</given-names></name><name><surname>Nishimura</surname><given-names>KK</given-names></name><name><surname>Giroux</surname><given-names>DJ</given-names></name><name><surname>Detterbeck</surname><given-names>F</given-names></name><name><surname>Cardillo</surname><given-names>G</given-names></name><name><surname>Edwards</surname><given-names>JG</given-names></name><name><surname>Fong</surname><given-names>KM</given-names></name><name><surname>Giuliani</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Kernstine</surname><given-names>KH</given-names><suffix>Sr</suffix></name><etal/></person-group><article-title>The international association for the study of lung cancer lung cancer staging project: Proposals for revision of the TNM stage groups in the forthcoming (ninth) edition of the TNM classification for lung cancer</article-title><source>J Thorac Oncol</source><volume>19</volume><fpage>1007</fpage><lpage>1027</lpage><year>2024</year><pub-id pub-id-type="doi">10.1016/j.jtho.2024.02.011</pub-id></element-citation></ref>
<ref id="b24-mmr-32-6-13694"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehmsen</surname><given-names>S</given-names></name><name><surname>Pedersen</surname><given-names>MH</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Terp</surname><given-names>MG</given-names></name><name><surname>Arslanagic</surname><given-names>A</given-names></name><name><surname>Hood</surname><given-names>BL</given-names></name><name><surname>Conrads</surname><given-names>TP</given-names></name><name><surname>Leth-Larsen</surname><given-names>R</given-names></name><name><surname>Ditzel</surname><given-names>HJ</given-names></name></person-group><article-title>Increased cholesterol biosynthesis is a key characteristic of breast cancer stem cells influencing patient outcome</article-title><source>Cell Rep</source><volume>27</volume><fpage>3927</fpage><lpage>3938.e6</lpage><year>2019</year><pub-id pub-id-type="doi">10.1016/j.celrep.2019.05.104</pub-id></element-citation></ref>
<ref id="b25-mmr-32-6-13694"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turley</surname><given-names>SJ</given-names></name><name><surname>Cremasco</surname><given-names>V</given-names></name><name><surname>Astarita</surname><given-names>JL</given-names></name></person-group><article-title>Immunological hallmarks of stromal cells in the tumour microenvironment</article-title><source>Nat Rev Immunol</source><volume>15</volume><fpage>669</fpage><lpage>682</lpage><year>2015</year><pub-id pub-id-type="doi">10.1038/nri3902</pub-id></element-citation></ref>
<ref id="b26-mmr-32-6-13694"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications</article-title><source>Cell Mol Immunol</source><volume>17</volume><fpage>807</fpage><lpage>821</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41423-020-0488-6</pub-id></element-citation></ref>
<ref id="b27-mmr-32-6-13694"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x00ED;nez-Jim&#x00E9;nez</surname><given-names>F</given-names></name><name><surname>Mui&#x00F1;os</surname><given-names>F</given-names></name><name><surname>Sent&#x00ED;s</surname><given-names>I</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Reyes-Salazar</surname><given-names>I</given-names></name><name><surname>Arnedo-Pac</surname><given-names>C</given-names></name><name><surname>Mularoni</surname><given-names>L</given-names></name><name><surname>Pich</surname><given-names>O</given-names></name><name><surname>Bonet</surname><given-names>J</given-names></name><name><surname>Kranas</surname><given-names>H</given-names></name><etal/></person-group><article-title>A compendium of mutational cancer driver genes</article-title><source>Nat Rev Cancer</source><volume>20</volume><fpage>555</fpage><lpage>572</lpage><year>2020</year><pub-id pub-id-type="doi">10.1038/s41568-020-0290-x</pub-id></element-citation></ref>
<ref id="b28-mmr-32-6-13694"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Azoitei</surname><given-names>A</given-names></name><name><surname>Eiseler</surname><given-names>T</given-names></name><name><surname>Eckstein</surname><given-names>M</given-names></name><name><surname>Hartmann</surname><given-names>A</given-names></name><name><surname>Stilgenbauer</surname><given-names>S</given-names></name><name><surname>Elati</surname><given-names>M</given-names></name><name><surname>Hohwieler</surname><given-names>M</given-names></name><etal/></person-group><article-title>Impairment of &#x03B1;-tubulin and F-actin interactions of GJB3 induces aneuploidy in urothelial cells and promotes bladder cancer cell invasion</article-title><source>Cell Mol Biol Lett</source><volume>29</volume><fpage>94</fpage><year>2024</year><pub-id pub-id-type="doi">10.1186/s11658-024-00609-2</pub-id></element-citation></ref>
<ref id="b29-mmr-32-6-13694"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Otano</surname><given-names>I</given-names></name><name><surname>Ucero</surname><given-names>AC</given-names></name><name><surname>Zugazagoitia</surname><given-names>J</given-names></name><name><surname>Paz-Ares</surname><given-names>L</given-names></name></person-group><article-title>At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC</article-title><source>Nat Rev Clin Oncol</source><volume>20</volume><fpage>143</fpage><lpage>159</lpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41571-022-00718-x</pub-id></element-citation></ref>
<ref id="b30-mmr-32-6-13694"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Su</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name></person-group><article-title>Anti-PD-1/PD-L1 therapy for non-small-cell lung cancer: Toward personalized medicine and combination strategies</article-title><source>J Immunol Res</source><volume>2018</volume><fpage>6984948</fpage><year>2018</year><pub-id pub-id-type="doi">10.1155/2018/6984948</pub-id></element-citation></ref>
<ref id="b31-mmr-32-6-13694"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santoni-Rugiu</surname><given-names>E</given-names></name><name><surname>Melchior</surname><given-names>LC</given-names></name><name><surname>Urbanska</surname><given-names>EM</given-names></name><name><surname>Jakobsen</surname><given-names>JN</given-names></name><name><surname>Stricker</surname><given-names>K</given-names></name><name><surname>Grauslund</surname><given-names>M</given-names></name><name><surname>S&#x00F8;rensen</surname><given-names>JB</given-names></name></person-group><article-title>Intrinsic resistance to EGFR-tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Differences and similarities with acquired resistance</article-title><source>Cancers (Basel)</source><volume>11</volume><fpage>923</fpage><year>2019</year><pub-id pub-id-type="doi">10.3390/cancers11070923</pub-id></element-citation></ref>
<ref id="b32-mmr-32-6-13694"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>Solomon</surname><given-names>BJ</given-names></name><name><surname>Besse</surname><given-names>B</given-names></name><name><surname>Bauer</surname><given-names>TM</given-names></name><name><surname>Lin</surname><given-names>CC</given-names></name><name><surname>Soo</surname><given-names>RA</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Ou</surname><given-names>SI</given-names></name><name><surname>Clancy</surname><given-names>JS</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><etal/></person-group><article-title>ALK Resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer</article-title><source>J Clin Oncol</source><volume>37</volume><fpage>1370</fpage><lpage>1379</lpage><year>2019</year><pub-id pub-id-type="doi">10.1200/JCO.18.02236</pub-id></element-citation></ref>
<ref id="b33-mmr-32-6-13694"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Drilon</surname><given-names>A</given-names></name><name><surname>Siena</surname><given-names>S</given-names></name><name><surname>Dziadziuszko</surname><given-names>R</given-names></name><name><surname>Barlesi</surname><given-names>F</given-names></name><name><surname>Krebs</surname><given-names>MG</given-names></name><name><surname>Shaw</surname><given-names>AT</given-names></name><name><surname>de Braud</surname><given-names>F</given-names></name><name><surname>Rolfo</surname><given-names>C</given-names></name><name><surname>Ahn</surname><given-names>MJ</given-names></name><name><surname>Wolf</surname><given-names>J</given-names></name><etal/></person-group><article-title>Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: Integrated analysis of three phase 1&#x2013;2 trials</article-title><source>Lancet Oncol</source><volume>21</volume><fpage>261</fpage><lpage>270</lpage><year>2020</year><pub-id pub-id-type="doi">10.1016/S1470-2045(19)30690-4</pub-id></element-citation></ref>
<ref id="b34-mmr-32-6-13694"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Qi</surname><given-names>C</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>M</given-names></name><name><surname>Gong</surname><given-names>J</given-names></name><etal/></person-group><article-title>Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer</article-title><source>J Immunother Cancer</source><volume>10</volume><fpage>e004703</fpage><year>2022</year><pub-id pub-id-type="doi">10.1136/jitc-2022-004703</pub-id></element-citation></ref>
<ref id="b35-mmr-32-6-13694"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Boshoff</surname><given-names>C</given-names></name></person-group><article-title>Toward personalized treatment approaches for non-small-cell lung cancer</article-title><source>Nat Med</source><volume>27</volume><fpage>1345</fpage><lpage>1356</lpage><year>2021</year><pub-id pub-id-type="doi">10.1038/s41591-021-01450-2</pub-id></element-citation></ref>
<ref id="b36-mmr-32-6-13694"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>RJ</given-names></name><name><surname>Singh</surname><given-names>PK</given-names></name><name><surname>Mehla</surname><given-names>K</given-names></name></person-group><article-title>The cholesterol pathway: Impact on immunity and cancer</article-title><source>Trends Immunol</source><volume>43</volume><fpage>78</fpage><lpage>92</lpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.it.2021.11.007</pub-id></element-citation></ref>
<ref id="b37-mmr-32-6-13694"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pavlova</surname><given-names>NN</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><article-title>The hallmarks of cancer metabolism: Still emerging</article-title><source>Cell Metab</source><volume>34</volume><fpage>355</fpage><lpage>377</lpage><year>2022</year><pub-id pub-id-type="doi">10.1016/j.cmet.2022.01.007</pub-id></element-citation></ref>
<ref id="b38-mmr-32-6-13694"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanahan</surname><given-names>D</given-names></name></person-group><article-title>Hallmarks of cancer: New dimensions</article-title><source>Cancer Discov</source><volume>12</volume><fpage>31</fpage><lpage>46</lpage><year>2022</year><pub-id pub-id-type="doi">10.1158/2159-8290.CD-21-1059</pub-id></element-citation></ref>
<ref id="b39-mmr-32-6-13694"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Z</given-names></name><name><surname>He</surname><given-names>F</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Simvastatin and Atorvastatin inhibit DNA replication licensing factor MCM7 and effectively suppress RB-deficient tumors growth</article-title><source>Cell Death Dis</source><volume>8</volume><fpage>e2673</fpage><year>2017</year><pub-id pub-id-type="doi">10.1038/cddis.2017.46</pub-id></element-citation></ref>
<ref id="b40-mmr-32-6-13694"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mullen</surname><given-names>PJ</given-names></name><name><surname>Yu</surname><given-names>R</given-names></name><name><surname>Longo</surname><given-names>J</given-names></name><name><surname>Archer</surname><given-names>MC</given-names></name><name><surname>Penn</surname><given-names>LZ</given-names></name></person-group><article-title>The interplay between cell signalling and the mevalonate pathway in cancer</article-title><source>Nat Rev Cancer</source><volume>16</volume><fpage>718</fpage><lpage>731</lpage><year>2016</year><pub-id pub-id-type="doi">10.1038/nrc.2016.76</pub-id></element-citation></ref>
<ref id="b41-mmr-32-6-13694"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Jung</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>YS</given-names></name><name><surname>Ahn</surname><given-names>JB</given-names></name><name><surname>Shin</surname><given-names>SJ</given-names></name><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Oh</surname><given-names>DY</given-names></name><name><surname>Shin</surname><given-names>DB</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name><name><surname>Lee</surname><given-names>N</given-names></name><etal/></person-group><article-title>Simvastatin plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as first-line chemotherapy in metastatic colorectal patients: A multicenter phase II study</article-title><source>Cancer Chemother Pharmacol</source><volume>64</volume><fpage>657</fpage><lpage>663</lpage><year>2009</year><pub-id pub-id-type="doi">10.1007/s00280-008-0913-5</pub-id></element-citation></ref>
<ref id="b42-mmr-32-6-13694"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>JC</given-names></name><name><surname>Hao</surname><given-names>WR</given-names></name><name><surname>Hsu</surname><given-names>YP</given-names></name><name><surname>Sung</surname><given-names>LC</given-names></name><name><surname>Kao</surname><given-names>PF</given-names></name><name><surname>Lin</surname><given-names>CF</given-names></name><name><surname>Wu</surname><given-names>AT</given-names></name><name><surname>Yuan</surname><given-names>KS</given-names></name><name><surname>Wu</surname><given-names>SY</given-names></name></person-group><article-title>Statins dose-dependently exert a significant chemopreventive effect on colon cancer in patients with chronic obstructive pulmonary disease: A population-based cohort study</article-title><source>Oncotarget</source><volume>7</volume><fpage>65270</fpage><lpage>65283</lpage><year>2016</year><pub-id pub-id-type="doi">10.18632/oncotarget.11263</pub-id></element-citation></ref>
<ref id="b43-mmr-32-6-13694"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Lv</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name></person-group><article-title>Dysregulation of cholesterol metabolism in cancer progression</article-title><source>Oncogene</source><volume>42</volume><fpage>3289</fpage><lpage>3302</lpage><year>2023</year><pub-id pub-id-type="doi">10.1038/s41388-023-02836-x</pub-id></element-citation></ref>
<ref id="b44-mmr-32-6-13694"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imaoka</surname><given-names>S</given-names></name><name><surname>Yoneda</surname><given-names>Y</given-names></name><name><surname>Sugimoto</surname><given-names>T</given-names></name><name><surname>Hiroi</surname><given-names>T</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Nakatani</surname><given-names>T</given-names></name><name><surname>Funae</surname><given-names>Y</given-names></name></person-group><article-title>CYP4B1 is a possible risk factor for bladder cancer in humans</article-title><source>Biochem Biophys Res Commun</source><volume>277</volume><fpage>776</fpage><lpage>780</lpage><year>2000</year><pub-id pub-id-type="doi">10.1006/bbrc.2000.3740</pub-id></element-citation></ref>
<ref id="b45-mmr-32-6-13694"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Kong</surname><given-names>S</given-names></name><name><surname>Tao</surname><given-names>M</given-names></name><name><surname>Ju</surname><given-names>S</given-names></name></person-group><article-title>The potential role of RNA N6-methyladenosine in cancer progression</article-title><source>Mol Cancer</source><volume>19</volume><fpage>88</fpage><year>2020</year><pub-id pub-id-type="doi">10.1186/s12943-020-01204-7</pub-id></element-citation></ref>
<ref id="b46-mmr-32-6-13694"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x00FC;ller</surname><given-names>S</given-names></name><name><surname>Gla&#x00DF;</surname><given-names>M</given-names></name><name><surname>Singh</surname><given-names>AK</given-names></name><name><surname>Haase</surname><given-names>J</given-names></name><name><surname>Bley</surname><given-names>N</given-names></name><name><surname>Fuchs</surname><given-names>T</given-names></name><name><surname>Lederer</surname><given-names>M</given-names></name><name><surname>Dahl</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner</article-title><source>Nucleic Acids Res</source><volume>47</volume><fpage>375</fpage><lpage>390</lpage><year>2019</year><pub-id pub-id-type="doi">10.1093/nar/gky1012</pub-id></element-citation></ref>
<ref id="b47-mmr-32-6-13694"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Gu</surname><given-names>Z</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Nie</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>J</given-names></name><name><surname>Cheng</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name></person-group><article-title>IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression</article-title><source>Theranostics</source><volume>11</volume><fpage>1100</fpage><lpage>1114</lpage><year>2021</year><pub-id pub-id-type="doi">10.7150/thno.49345</pub-id></element-citation></ref>
<ref id="b48-mmr-32-6-13694"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Peng</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name></person-group><article-title>KRT6A promotes EMT and cancer stem cell transformation in lung adenocarcinoma</article-title><source>Technol Cancer Res Treat</source><volume>19</volume><fpage>1533033820921248</fpage><year>2020</year><pub-id pub-id-type="doi">10.1177/1533033820921248</pub-id></element-citation></ref>
<ref id="b49-mmr-32-6-13694"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huo</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Zheng</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Tao</surname><given-names>L</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>LP</given-names></name></person-group><article-title>GJB3 promotes pancreatic cancer liver metastasis by enhancing the polarization and survival of neutrophil</article-title><source>Front Immunol</source><volume>13</volume><fpage>983116</fpage><year>2022</year><pub-id pub-id-type="doi">10.3389/fimmu.2022.983116</pub-id></element-citation></ref>
<ref id="b50-mmr-32-6-13694"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mohammadalipour</surname><given-names>A</given-names></name><name><surname>Showalter</surname><given-names>CA</given-names></name><name><surname>Muturi</surname><given-names>HT</given-names></name><name><surname>Farnoud</surname><given-names>AM</given-names></name><name><surname>Najjar</surname><given-names>SM</given-names></name><name><surname>Burdick</surname><given-names>MM</given-names></name></person-group><article-title>Cholesterol depletion decreases adhesion of non-small cell lung cancer cells to E-selectin</article-title><source>Am J Physiol Cell Physiol</source><volume>325</volume><fpage>C471</fpage><lpage>C482</lpage><year>2023</year><pub-id pub-id-type="doi">10.1152/ajpcell.00197.2020</pub-id></element-citation></ref>
<ref id="b51-mmr-32-6-13694"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ngwa</surname><given-names>VM</given-names></name><name><surname>Edwards</surname><given-names>DN</given-names></name><name><surname>Philip</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>Microenvironmental metabolism regulates antitumor immunity</article-title><source>Cancer Res</source><volume>79</volume><fpage>4003</fpage><lpage>4008</lpage><year>2019</year><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-19-0617</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-mmr-32-6-13694" position="float">
<label>Figure 1.</label>
<caption><p>Consensus clustering identifying two LUAD subgroups with distinct cholesterol metabolism characteristics. (A) Differential expression of 44 prognostically relevant cholesterol metabolism-related genes in LUAD. (B) Consensus clustering matrix. (C) CDF curves for clusters. (D) Relative change in the area under the CDF curve. (E) Kaplan-Meier survival analysis. (F) Sankey diagram. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;P&#x003C;0.0001. CDF, cumulative distribution function; LUAD, lung adenocarcinoma.</p></caption>
<alt-text>Figure 1. Consensus clustering identifying two LUAD subgroups with distinct cholesterol metabolism characteristics. (A) Differential expression of 44 prognostically relevant cholesterol metabolism&#x2013;rel...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g00.tif"/>
</fig>
<fig id="f2-mmr-32-6-13694" position="float">
<label>Figure 2.</label>
<caption><p>Gene set enrichment analysis revealing differences in pathways between the two cholesterol metabolism subgroups. GO enrichment in (A) cluster 1 and (B) cluster 2. KEGG enrichment in (C) cluster 1 and (D) cluster 2. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes.</p></caption>
<alt-text>Figure 2. Gene set enrichment analysis revealing differences in pathways between the two cholesterol metabolism subgroups. GO enrichment in (A) cluster 1 and (B) cluster 2. KEGG enrichment in (C) clus...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g01.tif"/>
</fig>
<fig id="f3-mmr-32-6-13694" position="float">
<label>Figure 3.</label>
<caption><p>Tumor microenvironment assessment and prediction of immune cell infiltration. (A) Relative infiltration levels of 28 immune cells by single sample gene set enrichment analysis. Tumor microenvironment evaluation by ESTIMATE algorithm, including (B) immune score, (C) tumor purity and (D) ESTIMATE score. (E) Expression of key immune checkpoints in the two clusters. &#x002A;P&#x003C;0.05, &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;P&#x003C;0.001, &#x002A;&#x002A;&#x002A;&#x002A;P&#x003C;0.0001.</p></caption>
<alt-text>Figure 3. Tumor microenvironment assessment and prediction of immune cell infiltration. (A) Relative infiltration levels of 28 immune cells by single sample gene set enrichment analysis. Tumor microen...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g02.tif"/>
</fig>
<fig id="f4-mmr-32-6-13694" position="float">
<label>Figure 4.</label>
<caption><p>Construction and validation of the cholesterol metabolism gene signature. (A) LASSO Cox regression model for parameter (&#x03BB;) adjustment through 10-fold cross-validation. (B) Identification of five key CMRGs and their corresponding coefficients. (C) KM survival analysis in TCGA dataset. (D) Relationship between mortality rates and risk scores in TCGA dataset. (E) Expression patterns of key CMRGs in TCGA dataset. (F) KM survival analysis in GSE72094. (G) Relationship between mortality rates and risk scores in GSE72094. (H) Expression patterns of key CMRGs in GSE72094. KM, Kaplan-Meier; TCGA, The Cancer Genome Atlas; CMRGs, cholesterol metabolism-related genes.</p></caption>
<alt-text>Figure 4. Construction and validation of the cholesterol metabolism gene signature. (A) LASSO Cox regression model for parameter (&#x03BB;) adjustment through 10&#x2013;fold cross&#x2013;validation. (B) Identification o...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g03.tif"/>
</fig>
<fig id="f5-mmr-32-6-13694" position="float">
<label>Figure 5.</label>
<caption><p>Application of the nomogram in the prognosis of LUAD. (A) Univariate and (B) multivariate Cox regression analyses to evaluate the association between CMRGs risk signals and LUAD prognosis. (C) Nomogram for quantifying the likelihood of patient survival. (D) Receiver operating characteristic curves of nomogram performance. (E) Calibration curves. AUC, area under the curve; LUAD, lung adenocarcinoma; CMRGs, cholesterol metabolism-related genes.</p></caption>
<alt-text>Figure 5. Application of the nomogram in the prognosis of LUAD. (A) Univariate and (B) multivariate Cox regression analyses to evaluate the association between CMRGs risk signals and LUAD prognosis. (...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g04.tif"/>
</fig>
<fig id="f6-mmr-32-6-13694" position="float">
<label>Figure 6.</label>
<caption><p>TMB analysis in the high-risk lung adenocarcinoma group. (A) Top 20 genes with mutation frequencies in the high-risk group. (B) Top 20 genes with mutation frequencies in the low-risk group. (C) Comparison of TMB between high-risk and low-risk groups. (D) Correlation analysis between risk score and TMB. TMB, tumor mutation burden.</p></caption>
<alt-text>Figure 6. TMB analysis in the high&#x2013;risk lung adenocarcinoma group. (A) Top 20 genes with mutation frequencies in the high&#x2013;risk group. (B) Top 20 genes with mutation frequencies in the low&#x2013;risk group. ...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g05.tif"/>
</fig>
<fig id="f7-mmr-32-6-13694" position="float">
<label>Figure 7.</label>
<caption><p>Treatment response prediction based on the cholesterol metabolism gene signature. (A) TIDE score comparison between the two risk groups. (B) Response rate comparison between the two risk groups. (C) Sensitivity of different risk groups to chemotherapy drugs. &#x002A;&#x002A;&#x002A;P&#x003C;0.001. TIDE, Tumor Immune Dysfunction and Exclusion.</p></caption>
<alt-text>Figure 7. Treatment response prediction based on the cholesterol metabolism gene signature. (A) TIDE score comparison between the two risk groups. (B) Response rate comparison between the two risk gro...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g06.tif"/>
</fig>
<fig id="f8-mmr-32-6-13694" position="float">
<label>Figure 8.</label>
<caption><p>Effect of GJB3 expression on LUAD progression in <italic>in vitro</italic> experiments. (A) Knockdown efficiency of GJB3 after siRNA transfection, demonstrated by western blotting. (B) Knockdown of GJB3 enhanced LUAD cell proliferation. (C) EdU and (D) colony formation assays showed a decrease in the proportion of LUAD cells in the proliferative state after GJB3 knockdown (magnification, &#x00D7;200). (E) Migration and (F) invasion of LUAD cells was decreased after GJB3 knockdown (magnification, &#x00D7;200). (G) Knockdown of GJB3 inhibited the expression of epithelial-mesenchymal transition-related genes. (H) Semi-quantitative analysis of western blotting in (A). &#x002A;&#x002A;P&#x003C;0.01, &#x002A;&#x002A;&#x002A;&#x002A;P&#x003C;0.0001. LUAD, lung adenocarcinoma; NC, negative control; siRNA, small interfering RNA.</p></caption>
<alt-text>Figure 8. Effect of GJB3 expression on LUAD progression in in vitro experiments. (A) Knockdown efficiency of GJB3 after siRNA transfection, demonstrated by western blotting. (B) Knockdown of GJB3 enha...</alt-text>
<graphic xlink:href="mmr-32-06-13694-g07.tif"/>
</fig>
</floats-group>
</article>
